Atopic Dermatitis

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.

New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.

In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

Peter Lio, MD, breaks down AdvanceAD-Tx testing and oral STAT6 degrader KT-621 in the atopic dermatitis pipeline.

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.

Dallas allergist-immunologists discuss real-world use of non-steroidal topicals in AD, steroid phobia, and the nematode story.

In this discussion, Eichenfield discusses which advances in eczema he sees as most impactful and where unmet needs remain for pediatric patients.

This Q&A highlights recent data and FDA approvals described in the pediatric atopic dermatitis space by Lawrence Eichenfield, MD.

In this interview, Lawrence Eichenfield, MD, reviews new data on topical and systemic treatments such as tapinarof and ruxolitinib in atopic dermatitis.

Lawrence Eichenfield, MD, breaks down new AAD pediatric atopic dermatitis guidelines, covering prevention strategies and linked comorbidities.

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Linda Stein Gold, MD, explains what new ADORING data reveal about tapinarof cream for atopic dermatitis across age cohorts.

New phase 3 data show tapinarof cream (VTAMA) delivered early, consistent efficacy across pediatric and adult age groups with atopic dermatitis.

Lebrikizumab improved itch, quality of life, and infection rates in kids with moderate-to-severe atopic dermatitis, ADorable-1 results suggest.